Stanley P. L. Leong

ORCID: 0000-0002-0047-0112
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cutaneous Melanoma Detection and Management
  • Immunotherapy and Immune Responses
  • Nonmelanoma Skin Cancer Studies
  • Melanoma and MAPK Pathways
  • Breast Cancer Treatment Studies
  • CAR-T cell therapy research
  • Cancer Genomics and Diagnostics
  • Cancer Cells and Metastasis
  • Cancer Immunotherapy and Biomarkers
  • bioluminescence and chemiluminescence research
  • Sarcoma Diagnosis and Treatment
  • Breast Lesions and Carcinomas
  • Monoclonal and Polyclonal Antibodies Research
  • Optical Coherence Tomography Applications
  • Breast Implant and Reconstruction
  • Cancer Diagnosis and Treatment
  • Cutaneous lymphoproliferative disorders research
  • Cancer Research and Treatments
  • Lymphatic System and Diseases
  • Tumors and Oncological Cases
  • Allergic Rhinitis and Sensitization
  • Cell Adhesion Molecules Research
  • DNA and Nucleic Acid Chemistry
  • Virus-based gene therapy research
  • Cancer and Skin Lesions

California Pacific Medical Center
2016-2025

University of California, San Francisco
2010-2024

Sutter Health
2024

Moffitt Cancer Center
2011-2022

Henry Ford Hospital
2022

Stony Brook University
2022

State University of New York
2022

Stony Brook School
2022

University of Tampa
2022

University of Pennsylvania
2022

A mini-symposium was held in Montreal, Canada, at the International Surgical Week for Breast 2007 addressing question whether breast cancer is same disease Asian and Western countries. Numerous investigators from countries presented epidemiologic clinical outcome data of women with cancer. Although there are significant similarities, striking difference that peak age between 40 50 years countries, whereas 60 70 years. Also, incidence Asia rising associated increased mortality. In West,...

10.1007/s00268-010-0683-1 article EN cc-by-nc World Journal of Surgery 2010-07-06

Because of the paucity available tissue, little information has previously been regarding gene expression profiles primary melanomas. To understand molecular basis melanoma progression, we compared a series nevi, melanomas, and metastases. We found that metastatic melanomas exhibit two dichotomous patterns expression, which unexpectedly reflect differences already apparent in comparing laser-capture microdissected radial vertical phases large melanoma. Unsupervised hierarchical clustering...

10.1073/pnas.0501564102 article EN Proceedings of the National Academy of Sciences 2005-04-15

Purpose The aim of this study was to assess the independent prognostic value primary tumor mitotic rate compared with other clinical and pathologic features stages I II melanoma. Methods From American Joint Committee on Cancer (AJCC) melanoma staging database, information extracted for 13,296 patients disease who had data available. Results Survival times declined as increased. Ten-year survival ranged from 93% whose tumors 0 mitosis/mm 2 48% those ≥ 20/mm (P < .001). Mean number...

10.1200/jco.2010.31.5812 article EN Journal of Clinical Oncology 2011-04-26

Indications for sentinel lymph node biopsy (SLNB) thin melanoma are continually evolving. We present a large multi-institutional study to determine factors predictive of (SLN) metastasis in melanoma.Retrospective review the Sentinel Lymph Node Working Group database from 1994 2012 identified 1,250 patients who had an SLNB and melanomas (≤ 1 mm). Clinicopathologic characteristics were correlated with SLN status outcome.SLN metastases detected 65 (5.2%) patients. On univariable analysis, rates...

10.1200/jco.2013.50.1114 article EN Journal of Clinical Oncology 2013-11-05

National Comprehensive Cancer Network guidelines recommend sentinel lymph node biopsy (SLNB) for patients with > 10% risk of positivity, consider SLNB 5–10% risk, and foregoing < 5% risk. The integrated 31-gene expression profile (i31-GEP) algorithm combines the 31-GEP clinicopathologic variables, estimating SLN positivity i31-GEP prediction accuracy was assessed in T1-T2 tumors enrolled prospective, multicenter DECIDE study (n = 322). To determine if incorporating into decision-making...

10.1186/s12957-024-03640-x article EN cc-by-nc-nd World Journal of Surgical Oncology 2025-01-03

Journal Article Coexpression of Vimentin and Keratins by Human Melanoma Tumor Cells: Correlation With Invasive Metastatic Potential Get access Mary J. C. Hendrix, Hendrix * Department Anatomy, University Arizona College Medicine, The Cancer CenterTucson, Ariz *Correspondence to : Ph.D., Arizona, Tucson, AZ 85724. Search for other works this author on: Oxford Academic PubMed Google Scholar Elisabeth A. Seftor, Seftor Medicine Yi-Wen Chu, Chu Center, Richard E. B. Raymond Nagle, Nagle...

10.1093/jnci/84.3.165 article EN JNCI Journal of the National Cancer Institute 1992-02-05

[(99m)Tc]Tilmanocept is a CD206 receptor-targeted radiopharmaceutical designed for sentinel lymph node (SLN) identification. Two nearly identical nonrandomized phase III trials compared [(99m)Tc]tilmanocept to vital blue dye.Patients received and dye. SLNs identified intraoperatively as radioactive and/or were excised histologically examined. The primary end point, concordance, was the proportion of nodes detected by [(99m)Tc]tilmanocept; 90 % concordance prespecified minimum level. Reverse...

10.1245/s10434-012-2612-z article EN cc-by Annals of Surgical Oncology 2012-10-02

Melanoma brain metastasis is associated with an extremely poor prognosis, a median overall survival of 4-5 months. Since 2011, the patients stage IV melanoma has been significantly improved advent new targeted therapies and checkpoint inhibitors. We analyze outcomes diagnosed after introduction these novel drugs.We performed retrospective analysis our center database identified 79 between 2011 2015.The time from primary diagnosis to was 3.2 years. The duration initial 12.8 Following...

10.1186/s12885-018-4374-x article EN cc-by BMC Cancer 2018-04-27

ABSTRACT Background Although most patients with cutaneous melanoma (CM) will have a negative sentinel lymph node biopsy (SLNB), up to 20%–30% of these recur. The 31‐gene expression profile (31‐GEP) test has been prospectively validated identify at low (Class 1A), intermediate 1B/2A), and high 2B) risk SLN positivity recurrence. Methods DECIDE is prospective, multicenter study assess the effect 31‐GEP testing on SLNB performance rates in T1–T2 tumors considering long‐term outcomes. Here, we...

10.1002/cam4.70839 article EN cc-by Cancer Medicine 2025-04-01

<h3>Objective:</h3> To determine the optimal approach of selective sentinel lymph node (SLN) dissection in primary malignant melanoma. <h3>Design:</h3> Consecutive patient study. Prior to SLN and wide local excision melanoma biopsy site, technetium Tc 99m sulfur colloid was injected intradermally around or site mark SLN. Isosulfan blue (Lymphazurin, Hirsch Industries Inc, Richmond, Va) at immediately before surgical procedure. <h3>Setting:</h3> Teaching hospital tertiary care referral...

10.1001/archsurg.1997.01430300108021 article EN Archives of Surgery 1997-06-01

The cytogenetic findings in 31 liposarcomas from 26 patients are reported. Four other tumors did not grow. Three histologic types represented this analysis. well-differentiated were characterized by telomeric associations, large marker chromosomes and ring chromosomes, some cases, double minutes. pleomorphic contained very high clonal chromosomal numbers with near-tetraploid modes numerous variable, often unidentifiable, abnormalities. myxoid primarily a t(12;16)(q13;pll) as the sole...

10.1002/1097-0142(19920515)69:10<2484::aid-cncr2820691017>3.0.co;2-2 article EN Cancer 1992-05-15

To evaluate the efficacy and toxicity of gamma knife radiosurgery in treatment melanoma metastases to brain.We retrospectively reviewed 55 patients with single or multiple intracranial treated at University California, San Francisco, from 1991 through 1995. Sixteen were for recurrence following previous radiation therapy, 11 received as a boost whole-brain 28 had alone initial management brain metastases. The median minimum tumor dose 140 lesions was 19 Gy (range, 10-22 Gy) prescribed 35%...

10.1227/01.neu.0000309957.49508.22 article EN Neurosurgery 2006-08-01
Coming Soon ...